Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene: another selective estrogen modulator.

J A Kellen1

  • 1Department of Pathobiology and Laboratory Medicine, University of Toronto, Sunnybrook and Women's Health Science Center, Toronto, Ontario M4N 3M5, Canada. eljan@sprint.ca

In Vivo (Athens, Greece)
|March 13, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Raloxifene.

Current drug targets·2001
Same author

Chemoprevention of cancer: an ongoing saga.

In vivo (Athens, Greece)·2000
Same author

Genomic effects of tamoxifen.

Anticancer research·1996
Same author

The effect of toremifene on the expression of genes in a rat mammary adenocarcinoma.

In vivo (Athens, Greece)·1996
Same author

The effect of Toremifene on the expression of some genes in human mononuclear cells.

In vivo (Athens, Greece)·1995
Same author

Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers.

International journal of cancer·1994
Same journal

Time-Dependent Inflammatory Cytokine Responses in a Human Fetal Membrane Dual-Compartment Model.

In vivo (Athens, Greece)·2026
Same journal

Impact of COVID-19 Vaccine Type on the Efficacy and Safety of Nivolumab in Patients With Metastatic Non-small-cell Lung Cancer: A Multicenter Study.

In vivo (Athens, Greece)·2026
Same journal

Nutritional Support for Treatment Continuity and Survival in Advanced Gastric Cancer: A Propensity Score-matched Study.

In vivo (Athens, Greece)·2026
Same journal

Efficacy of Switching from Prior Nonsteroidal Anti-inflammatory Drugs to Transdermal Diclofenac in Cancer Pain Management.

In vivo (Athens, Greece)·2026
Same journal

Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells <i>In Vitro</i>.

In vivo (Athens, Greece)·2026
Same journal

Prognostic Value of Liver Function-based Scores in Hepatocellular Carcinoma Patients Undergoing Liver Transplantation.

In vivo (Athens, Greece)·2026
See all related articles

Raloxifene, an antiestrogen, modulates estrogen effects and offers benefits beyond cancer by reducing bone loss and atherogenesis without stimulating the endometrium.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Estrogens are key stimulators of tumor cell proliferation.
  • Endocrine manipulation has a history of success in cancer prevention.
  • Antiestrogens, like Raloxifene, are a class of compounds that interfere with estrogen effects.

Purpose of the Study:

  • To explore the multifaceted actions of Raloxifene beyond its role as an antiestrogen.
  • To investigate Raloxifene's effects on estrogen-sensitive conditions and its broader health implications.

Main Methods:

  • Review of existing literature on Raloxifene's mechanisms of action.
  • Analysis of Raloxifene's interactions with steroid receptors, cellular pathways, and gene expression.
  • Evaluation of clinical and preclinical data on Raloxifene's effects on bone, cardiovascular health, and endometrial tissue.

Related Experiment Videos

Main Results:

  • Raloxifene acts as an antagonist to estrogen effects via receptor binding.
  • It exhibits diverse actions including interaction with lipid cascades, DNA binding, and regulation of growth factors and genes (e.g., erB2, mdr1, p53).
  • Raloxifene reduces bone demineralization and atherogenesis and does not stimulate endometrial proliferation.

Conclusions:

  • Raloxifene possesses complex pharmacological actions extending beyond simple estrogen antagonism.
  • It demonstrates significant therapeutic potential in managing bone loss and cardiovascular disease.
  • Raloxifene offers a favorable profile by avoiding the carcinogenic stimulation of the endometrium associated with some other endocrine therapies.